Spyre Therapeutics Inc
SYRE
ISIN null / Valor 129513338
Spyre Therapeutics Inc
UMushroom community rating:
About company
Spyre Therapeutics Inc is a biotechnology company focused on developing innovative treatments for immune-mediated diseases, particularly Inflammatory Bowel Disease (IBD). The company is engaged in the creation of advanced antibodies and therapeutic combinations, leveraging precision immunology to enhance treatment efficacy and patient convenience. By concentrating on these areas, Spyre Therapeutics aims to address significant unmet medical needs in the field of immunology, offering potential breakthroughs in the management of complex immune disorders.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (11.10.2025):
Spyre Therapeutics Inc reported its second quarter of 2025 financial results, showcasing a robust cash position and increased investment in research and development. The company continues to advance its clinical pipeline with positive Phase 1 results and the initiation of key Phase 2 trials, positioning itself for sustained growth and innovation in the treatment of inflammatory bowel disease and rheumatic diseases.
Strong Cash Position
As of June 30, 2025, Spyre Therapeutics Inc held $526.6 million in cash, cash equivalents, and marketable securities, ensuring a financial runway into the second half of 2028.
Increased Research and Development
R&D expenses rose to $40.1 million in the second quarter of 2025 compared to $32.6 million in the same period last year. This increase was driven by higher clinical trial expenses and increased compensation costs, partially offset by reduced early-stage R&D activities.
Stable General and Administrative Expenses
General and Administrative expenses remained steady at $11.8 million for Q2 2025, slightly up from $11.5 million in Q2 2024.
Milestone Gains
The company recognized a $10.0 million gain from achieved milestones related to the 2023 sale of the legacy Aeglea asset pegzilarginase to Immedica, influenced by a favorable reimbursement decision in Europe.
Ongoing Clinical Progress
Spyre reported positive interim Phase 1 results for two next-generation TL1A antibodies and initiated the Phase 2 SKYLINE-UC platform study. Additionally, the Phase 2 SKYWAY-RD basket study is on track to begin in Q3 2025, with further proof-of-concept readouts planned through 2027.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1471 M
Market cap (USD)
724,273
Daily traded volume (Shares)
23.35 / 22.37
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Mehmet John Evans
Antonio Tramacere
Elsa Mhangami
EQUITIES OF THE SAME SECTOR
